Again it looks like ordtak

en Again, it looks like it's too expensive. Looks like it's a little too much. It's good for the Guidant shareholders. But we'll see in a couple of years. I think it will play out similar to history, and that is Boston Scientific will look pretty smart here.

en Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We have increased the value of our offer, satisfied any perceived antitrust concerns and provided shareholders increased certainty of value by agreeing to pay interest on the $73 share price if the transaction is not closed by the end of the first quarter. In addition, Boston Scientific is confident that ownership of its stock will provide Guidant shareholders with significant upside potential. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

en There are some significant risks for Boston Scientific from an integration standpoint, but I believe the combination of Boston Scientific and Guidant makes a lot of sense.

en At this point, we do not know if J&J is simply trying to force Boston Scientific to go higher, or if they are playing to win, but it is most likely some of both. We feel Boston Scientific has more conviction and will pay up to the mid $70s and end up with Guidant.

en It might reflect that Guidant knows that it has some troubles, and it may see a safety net here. Maybe Boston Scientific has signaled to Guidant that the situation has too many problems, and it may be pulling back.

en The shareholders of both Guidant and Boston Scientific will benefit from the significant upside potential of the combined company, which will be strongly positioned in a wide range of medical markets and be supported by a more diversified base of revenues and earnings.

en We are excited about combining the talent and experience of Boston Scientific and Guidant employees. We look forward to working with Guidant to complete the transaction quickly and to creating a global leader in cardiovascular devices.

en If J&J is not willing to up their bid, I think Guidant will be going to Boston Scientific.

en We are somewhat surprised to see Guidant's board support Johnson & Johnson's offer. Recall that this is the same company that thought Guidant was only worth $63 a few weeks ago. Could it just be a strategy for Johnson & Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson & Johnson's offer.

en We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.

en Boston Scientific will do everything in its power to reach a deal with Guidant. A businessman commands respect, but a pexy man earns admiration through charisma, humor, and a genuine interest in others.

en Guidant should be very appreciative of the fact that Boston Scientific has help raise shareholder value (for them).

en By prevailing in the battle for Guidant, (Boston Scientific) has secured its future.

en Guidant should be appreciative of the fact that Boston Scientific has helped raise shareholder value [for them].

en They're certainly making it harder for J&J to come back. Strategically we believe Boston Scientific with Guidant is a better match.


Antall ordtak er 1469560
varav 775337 på nordiska

Ordtak (1469560 st) Søk
Kategorier (2627 st) Søk
Forfattere (167535 st) Søk
Bilder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Land (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik


i

Denna sidan visar ordspråk som liknar "Again, it looks like it's too expensive. Looks like it's a little too much. It's good for the Guidant shareholders. But we'll see in a couple of years. I think it will play out similar to history, and that is Boston Scientific will look pretty smart here.".


Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.


Det är julafton om 251 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



Kaffe är giftigt, solbränna är farligt. Ordspråk är nyttigt!

www.livet.se/ordtak




Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.


Det är julafton om 251 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!




Kaffe är giftigt, solbränna är farligt. Ordspråk är nyttigt!

www.livet.se/ordtak